| Theme |
Menopausal derangement in bone metabolism |
| Title |
Primary hyperparathyroidism and menopause |
| Author |
Toshitsugu Sugimoto |
Division of Endocrinology / Metabolism, Neurology and Hematology / Oncology, Department of Clinical Molecular Medicine, Kobe University Graduate School of Medicine |
| [ Summary ] |
Primary hyperparathyroidism, a common endocrine disorder, is characterized by increased parathyroid cell proliferation and excessive secretion of parathyroid hormone (PTH). This disease occurs with a greater frequency in postmenopausal women. Although this reason remains uncertain, one possibility is that the estrogen-deficient skeleton is sensitized to the bone-resorbing action of PTH. The pathological state of this disease is also influenced by menopause, which can be partly explained by the interaction of PTH and estrogen on bone. Several lines of evidence have been available that estrogen replacement therapy as well as raloxifene, a selective estrogen receptor modulator, are effective for treatment of postmenopausal women with mild primary hyperparathyroidism. |